Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598239 | 1.00 | CA1 (0.31) | CA1CA9PRKCA | |
| SCHEMBL598237 | 1.00 | CA1 (0.31) | CA1CA9PRKCA | |
| SCHEMBL598238 | 1.00 | CA1 (0.31) | CA1CA9PRKCA | |
| SCHEMBL2963838 | 1.00 | CA1 (0.31) | CA1CA9PRKCA | |
| SCHEMBL6412846 | 0.78 | TNKS (0.33) | — | |
| SCHEMBL9697895 | 0.78 | RIPK1 (0.32) | — | |
| SCHEMBL5258370 | 0.76 | CA1 (0.38) | CA1CA9PRKCA | |
| SCHEMBL5258372 | 0.76 | CA1 (0.38) | CA1CA9PRKCA | |
| SCHEMBL5258371 | 0.76 | CA1 (0.38) | CA1CA9PRKCA | |
| SCHEMBL8506745 | 0.75 | SMYD2 (0.34) | CA1CA9PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772208-B2 | 2′,3′-dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections | PHARMASSET, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080280846-A1 | 2', 3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE INFECTIONS | PHARMASSET, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20040067877-A1 | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections | LELAND STANFORD JUNIOR UNIVERSITY | 2004-04-08 | — | — | US | disclosed |
| WO-2004013298-A2 | 2',3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVITRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280846-A1 | 2', 3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE INFECTIONS | DUT, DUS2, PNP | CA1 4698/4885CA9 3667/4885PRKCA 1724/4885 |
| US-20040067877-A1 | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections | DUT, PNP, DERA | CA1 4548/4885CA9 3397/4885PRKCA 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.